🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

11,276 results for “Te” Clear

  1. Armodafinil

    Teva Pharma GmbH

    Depression

    phase 3 small molecule completed

    4 trials

  2. Armodafinil 100 to 250 mg/day

    Teva Pharma GmbH

    Excessive Daytime Sleepiness

    phase 3 small molecule completed

    1 trial

  3. Armodafinil 150 mg/day

    Teva Pharma GmbH

    Obstructive Sleep Apnea

    phase 3 small molecule completed

    1 trial

  4. Armodafinil 150 mg/day

    Teva Pharma GmbH

    Excessive Sleepiness

    phase 3 small molecule completed

    1 trial

  5. Armodafinil 250 mg/day

    Teva Pharma GmbH

    Obstructive Sleep Apnea

    phase 3 small molecule completed

    1 trial

  6. Armstrong Albuterol Sulfate Inhalation Aerosol

    Amphastar France Pharmaceuticals

    Asthma

    phase 3 small molecule terminated

    1 trial

  7. Aromatase Inhibitors

    United Therapeutics Europe Ltd

    Breast Cancer

    phase 3 small molecule active

    1 trial

  8. Arsenic trioxide

    Teva Pharma GmbH

    Acute Myeloid Leukemia

    phase 3 small molecule terminated

    1 trial

  9. Arsenic trioxide

    Teva Pharma GmbH

    Acute Promyelocytic Leukemia

    phase 3 small molecule completed

    1 trial

  10. Artemether-lumefantrine

    AVENUE THERAPEUTICS, INC.

    Plasmodium Falciparum Malaria

    phase 3 small molecule completed

    1 trial

  11. Asparaginase

    Children's Hospital of Fudan University

    Acute Myeloid Leukemia

    phase 3 small molecule active

    1 trial

  12. Aspirin

    United Therapeutics Europe Ltd

    Node Positive HER2 Negative Breast Cancer

    phase 3 small molecule terminated

    1 trial

  13. Aspirin® protect 100 mg Magensaftresistente Tablette Acetylsalicylsäure, Aspirin® protect 300 mg Magensaftresistente Tablette Acetylsalicylsäure, Placebo of Aspirine 100 mg protect, placebo of aspirin 300 mg protect

    Pari Pharma GmbH

    Colorectal adenomas, Lynch syndrome

    phase 3 small molecule active

    1 trial

  14. Asundexian (BAY2433334)

    Bayer HealthCare AG

    Prevention of Stroke or Systemic Embolism

    phase 3 small molecule terminated

    1 trial

  15. Atenativ 1000 I.E. - Pulver und Lösungsmittel zur Herstellung einer Injektions- oder Infusionslösung, Atenativ, 50 IU/ml, prášek a rozpouštědlo pro infuzní roztok, Atenativ 500 I.E. - Pulver und Lösungsmittel zur Herstellung einer Injektions- oder Infusionslösung, Atenativ 50 i.e./ml prašek in vehikel za raztopino za infundiranje, Atenativ 50 IU/ml prášek a rozpouštědlo pro infuzní roztok, ATENATIV 50 UI/mL, poudre et solvant pour solution pour perfusion, ATENATIV 50 UI/mL, poudre et solvant pour solution p

    Lacuna Pharma Pty Ltd

    Acquired Antithrombin Deficiency (Heparin Resistance)

    phase 3 small molecule active

    1 trial

  16. Atezolizumab

    Hoffmann-La Roche

    Melanoma

    phase 3 small molecule completed

    1 trial

  17. Atezolizumab

    Hoffmann-La Roche

    Urothelial Carcinoma

    phase 3 small molecule completed

    2 trials

  18. Atezolizumab

    Hoffmann-La Roche

    Carcinoma, Hepatocellular

    phase 3 small molecule active

    1 trial

  19. Atezolizumab

    Jazz Pharmaceuticals Ireland Limited

    Small-Cell Lung Cancer

    phase 3 small molecule active

    1 trial

  20. Atezolizumab

    Hoffmann-La Roche

    Breast Cancer

    phase 3 small molecule completed

    1 trial

  21. Atezolizumab (MPDL3280A) [TECENTRIQ], an engineered anti-PDL1 antibody

    Hoffmann-La Roche

    Non-Squamous Non-Small Cell Lung Cancer, Squamous Non-Small Cell Lung Cancer

    phase 3 small molecule completed

    1 trial

  22. Atezolizumab (MPDL3280A), an engineered anti-PD-L1 antibody

    Hoffmann-La Roche

    Carcinoma, Non-Small-Cell Lung

    phase 3 small molecule completed

    1 trial

  23. Atezolizumab (MPDL3280A), an engineered anti-PD-L1 antibody

    Hoffmann-La Roche

    Non-Small Cell Lung Cancer

    phase 3 small molecule completed

    1 trial

  24. Atezolizumab (MPDL3280A), an engineered anti-PD-L1 antibody

    Hoffmann-La Roche

    Renal Cell Carcinoma

    phase 3 small molecule completed

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources